Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
Thyroid Carcinoma - Metastatic Sites Lung Bone Nodal
Conditions: official terms
Thyroid Diseases - Thyroid Neoplasms
Conditions: Keywords
radioiodine, differentiated thyroid cancers, dosimetry, metastases
Study Type
Study Phase
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Name: SPECT scan
Type: Other
Overall Status
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
Detailed Description
Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- age above 18

- histological confirmation of the differentiated thyroid carcinoma available

- WHO performance score 0-2

- metastatic sites lung and/or bone and/or nodal (radiologically measurable disease > 1 cm)

- life expectancy > 6 months

- patient has undergone total/near total thyroidectomy

- no past history of sensitivity/reaction to 1311

Exclusion Criteria:

- non iodine concentrating tumours

- received chemotherapy or radiotherapy in 6 weeks

- pregnant or breast feeding patients

- iodine contrast injection in last 3 months
Royal Marsden NHS Foundation Trust
London, Sutton, United Kingdom
Status: Recruiting
Contact: Dr Kate Newbold - 0208661 3638 -
Start Date
May 2008
Completion Date
July 2010
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Record processing date processed this data on July 28, 2015 page